Purpose of Fundraising
PRISM BioLab is utilizing its proprietary drug discovery platform to discover clinical candidate compounds for new targets, and is moving forward with pre-clinical studies to enter clinical trials as its third pipeline, while aiming for further growth by strengthening its R&D structure and establishing internal controls.
Comments from investors
Hiroki Narita, President and Representative Director, DCI Partners K.K. (Lead Investor)
We are pleased to participate as a lead investor in PRISM BioLab's PepMetics™, which we believe is a highly promising technology that can target previously difficult-to-discover drug targets with small molecule compounds. We hope that the funds raised will further accelerate our research and development efforts and lead to the creation of innovative drugs."
■Newton BioCapital Partners SPRL (Corydon Investor) Alan Partons, Managing Partner and President
As co-lead investors and as a Belgium-based fund, we are very pleased to support this innovative technology from Japan," said Dr. Jacques Bourdieu, CEO of PRISM, "PRISM's library consists of compounds that mimic α-helix and β-turn and are able to inhibit interactions between naturally modified proteins, a new target for bladder cancer and a variety of other diseases. It can inhibit interactions between naturally-denatured proteins, which are emerging targets for a variety of diseases, including bladder cancer. PRISM's recent partnerships with global pharmaceutical companies also show great potential for its unique approach. With this funding, we look forward to helping PRISM become one of the leading companies in drug discovery."
Haruhiko Uchiyama, President & CEO, DBJ Capital K.K.
We have made significant progress in both the pipeline and collaborative research with pharmaceutical companies using our platform technology since our last investment, and have made an additional investment. We expect that the funds obtained from this financing will further accelerate PRISM's R&D. As an existing investor, we will continue to support PRISM. As an existing investor, we will continue to support PRISM."
Mitsuru Miyata, President and Representative Director, Healthcare Innovation, Inc.
We have out-licensed our technology to a well-known big pharma and are on track with the development of two in-house new drugs that have entered clinical trials. We look forward to PRISM BioLab, with its unique peptide design technology, as a pioneer in the coming era of middle-molecular drugs.
Ichiro Nagata, President and Representative Director, Gemseki Corporation (Shin Nihon Kagaku & Co., Ltd., Corporate Venture Capital)
In addition to our business development platform business, we are actively investing in startups with groundbreaking technologies. We are confident that PRISM BioLab will be a part of supporting drug discovery that contributes to humanity and society."
Comment from Mr. Dai Takehara, Representative Director
We would like to express our sincere gratitude to our existing investors and to the investors who have made this significant donation. With the funds we have raised, we will continue to promote our research and development to raise global awareness of our drug discovery platform and to create many new therapeutics."
About PRISM BioLab
PRISM BioLab aims at drug discovery through the regulation of protein-protein interactions (PPIs) by small molecule compounds, utilizing its proprietary alpha-helix and beta-turn mimetic technology PRISM has developed a proprietary peptide mimetic technology called PepMetics™", a proprietary peptidomimetic technology that regulates PPI signaling in cells, and is creating a clinical pipeline in oncology and fibrosis, as well as partnering with a number of leading pharmaceutical companies in Japan and abroad to address new drug targets.
| name of company | PRISM BioLab Inc. |
| Establishment | November 2006 |
| Location | Shonan Eye Park, 2-26-1 Muraoka Higashi, Fujisawa City, Kanagawa Prefecture |
| representative | Dai Takehara |
| Business Overview | Drug Discovery Technology Development and Drug Discovery |
| uniform resouce locator | http://www.prismbiolab.com/ |









